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This study is part of a multi- country matched cohort study designed to estimate the risk of long 
term neurodevelopmental of children exposed to iGBS. The specific objective of this paper is to 
compare NDI across domains of iGBS survivors with a matched non-GBS group in our population.  
Methods 
Survivors of iGBS in a south Indian hospital were identified and recruited between January 2020 and 
April 2021. Cases were compared with age and gender matched non-GBS children. Participants were 
assessed using Bayley Scales of infant and toddler development (BSID-III), Wechsler Preschool and 
Primary Scale of Intelligence (WPPSI- IV), Wechsler Intelligence Scale for Children (WISC- V), Child 
behaviour checklist (CBCL) and Bruininks- Oseretsky Test of Motor Proficiency (BOT-2) depending on 
age. 
Results 
Our cohort comprised 35 GBS exposed and 65 matched non-GBS children, aged 1- 14 years. iGBS 
exposed group had 17 (48.6%) children with impairment in at least one domain compared to 25 
(38%) in the non-GBS group [Unadjusted OR- 1.51, 95%CI 0.65- 3.46], 9 (26%) children with ‘multi 
domain impairment’ compared to 10 (15.4%) in the non-GBS group [Unadjusted OR- 1.90, 95% CI 
0.69- 5.24] and 1 (2.9%) child with moderate to severe impairment compared to 3 (4.6%) in the non-
GBS group [Unadjusted OR- 0.60, 95%CI 0.06- 6.07]. In the iGBS group, more children had motor 
impairments compared to the non-GBS group [Unadjusted OR- 10.7, 95%CI 1.19- 95.69, p= 0.034] 
Conclusion 
Children with iGBS seem at higher risk of developing motor impairments compared to a non-GBS 
group.  
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TEXT BOX 1: KEY FINDINGS 
1. WHAT IS KNOWN and WHAT IS NEW? 
There are an estimated 392,000 children worldwide with invasive Group B Streptococcal Disease 
(iGBS), with the highest numbers in Sub Saharan Africa and Asia. Globally there are almost no 
published studies of neurodevelopmental impairment (NDI) amongst iGBS survivors from low and 
middle-income countries (LMIC). This is the first study from Asia to examine neurodevelopment of 
iGBS survivors using standardised developmental assessment tools across several domains.   
2. WHAT DID WE DO AND WHAT DID WE FIND? 
We identified 35 survivors of iGBS aged 1- 14 years and 65 matched non-GBS children, undertaking 
standardised assessments of NDI. The iGBS exposed children had a trend towards greater NDI, but 
this was not statistically significant [Unadjusted OR1.51, 95%CI 0.65- 3.46]. An important limitation 
of this study was that some children were not able to come due to travel restrictions during the 
COVID-19 pandemic, reducing the capture especially of both iGBS and non-GBS cohort. 
3. WHAT TO DO NOW IN PROGRAMMES? 
Early interventional services and follow up programs are required for survivors of iGBS to optimise 
neurodevelopmental outcomes.  
4. WHAT NEXT IN RESEARCH? 
There is a need for culturally appropriate measurement tools especially in measurement of language 
and cognition. Larger studies are needed to estimate the incidence of NDI in this population and to 
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The estimated incidence of severe neonatal infections in low and middle-income countries (LMIC)  is 
6.9 million. Invasive Group B Streptococcus disease (iGBS), an infection that presents as sepsis or 
meningitis, is a leading cause of neonatal sepsis with reported incidence of 0.49 per 1000 live births. 
Intrauterine and neonatal insults, contribute to a high risk of developing long term 
neurodevelopmental impairment (NDI) including cognitive, motor (e.g. cerebral palsy), hearing and 
visual impairment domains. Bacterial meningitis especially in neonates is a notable cause of NDI, 
with pathophysiological disruptions such as cerebral inflammation and oedema. After neonatal 
meningitis, an estimate of moderate to severe NDI is 23% [95% CI: 19 – 26%]. A systematic review of 
NDI of GBS survivors found moderate to severe NDI in 18% of meningitis survivors, but no useable 
data after iGBS sepsis. This review included 18 studies from upper- and middle-income countries 
with paucity of data for patients older than 2 years, and recommended future studies assessed the 
total burden of GBS disease in older children and assessing all developmental domains using valid 
assessment tools. There are no published studies that assessed neurodevelopment outcomes of 
iGBS survivors in an Asian population.  
AIM and OBJECTIVES 
This paper is part of a series of 10 papers reporting a value proposition for maternal vaccines against 
GBS by WHO. The aim of this paper is to present data collected in India as part of a multi-country 
study describing neurodevelopmental outcomes of iGBS survivors by domains of cognition, 
language, motor skills and behaviour and comparison with a non-GBS group.  
The objectives of the paper are to:  
(1) Describe a cohort of iGBS survivors and a matched non-GBS cohort 
(2) Evaluate the risk of NDI and categorise severity in the domains of vision, hearing, cognition, 
language, motor skills and behaviour in the iGBS cohort when compared to a non-GBS group. 
METHODS 
Setting: The study setting was a tertiary care teaching hospital in south India (Figure 1). This hospital 
is a referral perinatal centre catering to the population of four adjoining districts of three 
neighbouring states. The 75 bedded Neonatal unit with Level 3 facilities, has admissions of over 2500 
infants every year. There are about 12,000-14,000 births/year and the neonatal mortality rate 
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NMR in 2019- 21.7/1000 live births). The hospital has a risk based intrapartum antibiotic policy for 
GBS prophylaxis since 2003, with no national policy for the same. A multinational study in 2017 
found the prevalence of GBS colonisation among pregnant women in the institution was 20.9 %8. 
The  incidence of GBS disease between 1998 to 2010 in the institution was 0.76/1000 live births, of 
which incidence of early onset sepsis was 0.68/ 1000 live births [95%CI: 0.52- 0.83]. 
Study design: The study was a matched cohort study. Exposed were survivors of infant iGBS disease, 
henceforth termed as ‘iGBS survivors’, and unexposed were individuals with no GBS identified. This 
study is part of a multi-centric trial on the long-term outcomes of GBS survivors in LMICs; study 
protocol has already been published. 
Participants: iGBS survivors born between August 2006 to July 2018, were identified from the 
hospital’s database. As per protocol, children born < 32 weeks were excluded. Additional criterion 
for inclusion was knowledge of English or Tamil for administration of neurodevelopmental 
assessments. 
Parents were contacted telephonically and via post with an invitation to attend the 
neurodevelopmental assessment. Home visits though initially planned, were not executed due to 
the COVID pandemic during the period of recruitment. Exposure to GBS disease was defined as GBS 
isolated in blood culture between 0-89 days of the infant’s life. This study did not differentiate GBS 
sepsis or GBS meningitis. In our cohort, none of the babies with ‘meningitis’ had a positive CSF 
culture, which is the gold standard for diagnosis but were diagnosed based on high CSF counts or 
protein. 
Non-GBS children were matched for gender and age of ± 2 months of the iGBS survivors. We aimed 
to recruit 3:1 non-GBS to exposed children. Non-GBS children were recruited by identifying and 
contacting case- matched children from the hospital records, via the Immunisation clinic and 
through distribution of posters in the community.  No exclusion criteria were placed except a 
positive history of GBS infection in early infancy. There was a time lag between recruitment of 
exposed and children due to government imposed lock down measures to contain COVID infection.  
Recruitment was from January 2020 to April 2021. Once the family arrived at the hospital, written 
informed consent and child assent were obtained. The demographic, health and economic health 
questionnaire, and the EQ5D questionnaire were administered to the caregiver. The children’s 
anthropometry was measured, vision and hearing assessed and the neurodevelopmental 
assessments and relevant questionnaires administered. Information was collected on paper forms, 
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The study assessment team consisted of 3 occupational therapists, 2 psychologists, a fieldworker 
and a data entry operator. All team members were trained using an 8-session training module, 
covering standard guidelines for assessment of anthropometry, vision and hearing, administration of 
questionnaires and data entry. They were also certified in the administration, interpretation and 
scoring of the assessment tools. 
Neurodevelopmental assessments: 
Children aged below 42 months: Children aged 42 months or below were assessed using the Bayley 
Scales of Infant and Toddler development, Third Edition (BSID-3) for cognition, language, motor 
skills, socio-emotional skills and adaptive behaviour. The BSID is a globally accepted goal standard in 
child assessment and has recently been used in a number of large studies in our population. 
Children aged above 42 months: In children above 42 months, cognition was assessed using the 
Wechsler’s Preschool and Primary Scale of Intelligence- 4th Edition (WPPSI) or the Wechsler’s scale 
of Intelligence- 5th Edition (WISC-5), depending on the age. The WPPSI assesses cognitive abilities in 
children aged 2.5 to 7 years. It has 13 subtests, which yield scaled scores, standard scores and 
percentiles. The Wechsler’s Intelligence Scale for children- 5th Edition (WISC 5), is a commonly used 
assessment in school aged children. Both tools render composite scores for fluid reasoning, 
processing speed, verbal comprehension, visual spatial and working memory and a full scale IQ. The 
validity of both scales have been supported for use in LMIC and the WISC-4 standardised to the 
Indian population.   
Motor skills were assessed using the “Bruininks- Oseretsky Test of Motor Proficiency Second Edition 
(BOT-2)”.  It assesses fine and gross motor skills in children and youth aged 4 to 21 years. This study 
used the short form of the assessment which yields standard scores, percentile ranks and descriptive 
categorisation 
Behavioural outcomes for all children were measured using the Child Behaviour Checklist (CBCL). 
The CBCL is a parent-report questionnaire (comprised of two versions: a younger 1 ½ - 5 years and 6-
18 years) on which the child is rated on various behavioural and emotional problems. It assesses 
internalizing (i.e., anxious, depressive, and over controlled) and externalizing (i.e., aggressive, 
hyperactive, noncompliant,) behaviours. The questionnaire was translated and back translated into 
Tamil. Questions were read out to caregivers with limited literacy. 
The assessors were not blinded to participant group. During a developmental or psychological 
assessment, it is inevitable that parents share their traumatic NICU experience and this is not 
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assessors were not blinded to the groups. Since the assessment tools have stringent guidelines on 
scoring and interpretation, we did not anticipate bias due to the lack of blinding. Parental concerns 
were addressed by the team. Children with mild NDI had an additional appointment with the Unit’s 
Psychologist or Occupational therapist (depending on the domain of impairment). Parents were 
taught a home-based program and encouraged to attend regular follow up visits at 2 monthly 
intervals. Children with moderate to severe NDI were referred to the Institution’s Developmental 
Paediatric Unit. 
All assessments were scored according to their scoring manuals. NDI was defined based on the work 
by Global burden of Disease. Severity coding within each assessment was as follows (Supplementary 
table 2):  
Mild- if 1-2 SD below standardised mean 
Moderate- if 2-3 SD below standardised mean 
Severe- if≥ 3 SD below standardised mean 
‘Any impairment’: If the child had impairment in any domain (vision, hearing, cognition, language, 
motor or behaviour) 
‘Multi-domain impairment’: If there were impairments in more than one domain 
‘Moderate to Severe impairment’: If the child had moderate or severe impairment in any domain 
Socioeconomic status was assessed using the “Updated Modified Kuppuswamy SES” scale for the 
year 2020.  
Statistical Methods: 
Neurodevelopmental outcomes (NDO) were assessed separately for the 2 age groups- one group 
with children less than 42 months (who had BSID and CBCL assessments) and one group with 
children 43 months and above (who had a WISC or WPPSI, BOT and CBCL assessments) and 
combined (Supplemental Table 2). Domains of vision, hearing, cognition, language, motor abilities 
and behaviour were compared between exposed and non-GBS groups using a severity classification 
for NDI. 
Analysis was undertaken in SPSS software version 21. Descriptive statistics were reported using 
mean+/-SD for continuous variables; Categorical variables were reported using frequency and 
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was reported using two independent sample t test. Binary logistic regression was performed to 
arrive at the risk factor analysis. The Odds Ratio was reported along with the 95% Confidence 
Interval. A p value <0.05 was considered statistically significant. 
RESULTS 
Objective 1: Description of GBS survivors and a matched non-GBS group 
Out of 79 iGBS survivors contacted, 35 (44.3%) consented for participation and completed the 
assessment (Figure 2). Of the 35 children with iGBS, 33 (94.3%) had early onset sepsis and 2 (5.7%) 
had late onset sepsis. There were no significant differences in gender, prematurity, birth weight, 
gestational age, onset of sepsis, and rates of meningitis and chorioamnionitis between children who 
consented for participation and those who did not participate. Out of 158 matched non-GBS children 
approached for participation, 65(41.1%) children consented and completed the assessments (Figure 
2). One child in the non GBS group had sepsis, not caused by GBS in the neonatal period. Initially it 
was planned to recruit patients from the hospital data base using sequential sampling based on 
closest match. We were able to recruit around one third of the sample in this way. Due to the 
pandemic related travel restrictions, we later used convenient sampling by offering assessments to 
children who came for an immunisation visit and distribution of posters in the community. 
Participants were of ages 1- 14 years (M (SD) - 4.49 (3.47), Median- 3). There were no significant 
differences in demographic variables in exposed and non-GBS groups except in birth order (p= 0.003) 
(Table 1). Of the parents of children who underwent treatment for GBS sepsis in our hospital, who 
were contacted, none reported post discharge death. 
Objective 2: Risk of NDI in the GBS cohort when compared to a non-GBS group.  
Of the 35 iGBS survivors who participated in the study, all children had GBS sepsis and 4 (11%) also 
had meningitis. Among iGBS survivors, 17 (48.6%) children had impairment in at least one of the 
assessed domains as compared to 25 (38%) in the non-GBS group [Unadjusted OR- 1.51, 95%CI 0.65- 
3.46]; 9 (26%) children had impairment in more than one domain compared to 10 (15.4%) in the 
non-GBS group [Unadjusted OR- 1.90, 95% CI 0.69- 5.24]; and 1 (2.9%) child had moderate to severe 
impairment compared to 3 (4.6%) in the non-GBS group [Unadjusted OR- 0.60, 95%CI 0.06- 6.07]. 
The iGBS group had more children with motor impairments compared to the non-GBS group 
[Unadjusted OR- 10.7, 95%CI 1.19- 95.69, p= 0.033]. There were no differences in impairments in 
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[Unadjusted OR- 2.12, 95%CI 0.85- 5.28, p= 0.106] or behaviour [Unadjusted OR- 0.77, 95%CI 0.18- 
3.21, p=0.727] between the iGBS and non GBS groups (Table 2, Figure 3)).  
 
Looking at iGBS and non GBS groups combined, among children with ‘any impairment’, 27 (64%) had 
language impairment, 20 (47%) had cognitive impairment, 6 (14%) had motor impairment, and 11 
(26%) had behavioural impairment. Among children with ‘multi domain impairment’, 19 (100%) had 
language impairment, 17 (89%) had cognitive impairment, 6 (31.5%) had motor impairment, and 3 
(15.7%) had behavioural impairment. Among children with ‘moderate to severe impairment’, 3 
(75%) had language impairment, 4 (100%) had cognitive impairment, and 1 (25%) had motor 
impairment. 
Children below 42 months: There were 17 children in the exposed group and 32 in the non GBS 
group below 42 months. Four children (23.5%) in the exposed group and 1(3.1%) child in the non-
GBS group had “multi-domain impairment’ (p= 0.043).  
Children above 42 months: There were 18 children in the exposed group and 33 children in the non 
GBS group above 42 months. The exposed group had more children with motor impairments: 4 
(23.5%) in the exposed group and 1 (3.1%) child in the non-GBS group (p= 0.042). There was a trend 
towards lower scores in working memory Subscale (p= 0.06) and the Fullscale IQ (p= 0.06) in the 
exposed group (Table 2) compared to the non-GBS group. When children with ‘any impairment’ 
were excluded from analysis, the exposed group had lower FSIQ scores than the non-GBS group (p= 
0.014). 
DISCUSSION 
This study found that iGBS exposed children had approximately 50% higher odds of NDI but this was 
not statistically significant [Unadjusted OR1.51, 95%CI 0.65- 3.46]. Children in the iGBS group had 
more motor impairments compared to the non GBS group (p=0.033). An important limitation of this 
study was the small size due to COVID 19 pandemic travel restrictions, reducing the capture of both 
iGBS and the non-GBS cohort. This is the first published study in Asia examining NDI amongst iGBS 
survivors using standardized developmental assessment tools across several domains, and 
comparing with a matched non-GBS group. 
The iGBS exposed group had 17 (48.6%) children with ‘any impairment’ compared to 25 (38%) in the 
non-GBS group, 9 (26%) children with ‘multi domain impairment’ compared to 10 (15.4%) in the 
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compared to 3 (4.6%) in the non-GBS group. The exposed group had more children with motor 
impairments compared to the non-GBS group. Studies from south Africa found GBS affected children 
to be 13 times more likely to have any abnormal neurological signs when compared to non-GBS 
group at 6 months [5 (7.4%) in exposed and 1 (0.4% in non-GBS)], and a 3.5 fold (95% CI: 1.23- 10.04) 
increased odds of NDI compared to matched controls at 1 year [11 (24.4%) in exposed and 10 (7.1%) 
in non-GBS] using abnormal Denver- II scores to define NDI. A study on the association of GBS 
disease on NDI at a median age of 14 years found an increased risk of moderate to severe NDI with 
risk ratios of 1.7 [95%CI 1.44-2.18] in Denmark and 2.28 [1.64-3.17] in the Netherlands. In Denmark, 
the proportion of children with moderate to severe NDI at 10 years was 45 (4.6%) in the exposed 
group and 245 (2.5%) in the non-GBS group (RR1.82 [95% CI 1.33– 2.49]). In the Netherlands, the 
proportion of children who received special educational support at 10 years in the exposed group 
was 36 (14.3%) and 157 (6.2%) in the non-GBS group. A study in the United States found 2 (16%) 
children with neonatal GBS to have neurological impairments at 4 years. Children with GBS 
meningitis showed larger proportion of NDI: A meta-analysis of GBS meningitis survivors, followed 
up for more than 18 months, reported ‘any NDI’ in 32 % (95%CI, 25- 38) of children. 
There are several possibilities why the rates of moderate to severe NDI in this study were lower than 
in other studies. The small sample size and the possibility of selection bias (with families of children 
with less severe impairment more able to attend-especially during the pandemic) may have been 
factors. In our population, survivors of GBS disease are routinely enrolled in a follow up program 
post discharge, which includes an early stimulation program. Education about developmental 
milestones may have sensitised the parents to the child’s vulnerability resulting in active 
interventions to compensate for the child’s difficulties, so the lower rates of impairment may reflect 
earlier intervention. Systematic reviews have shown that while early intervention programs may not 
avert moderate to severe impairment, they have positive effects on cognitive development, with 
little influence on motor development. Another stipulation is the influence of genetic 
polymorphisms, such as interleukin-6 (rs1800795),which is associated with the development of 
cerebral palsy, that may account for racial differences in outcomes of  infants seen in other studies. 
Additionally, there may be measurement error due to varying developmental assessment tools used. 
The Cognitive, Language, and Motor composites of the Bayley-III, for example, have been shown to 
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In this study, most children with abnormal NDI had language impairments- 64% in ‘any impairment’, 
and 75% in ‘moderate to severe impairment’ and 100% in ‘multi-domain impairment’. This may be 
explained in two ways: The lack of culturally appropriate assessment tools or as inherent cultural 
differences in language acquisition. The mechanism of language development is proposed to be 
cultural than universal, implying its sensitivity to social factors and cultural context. 
The non-GBS group in this study has unexpected high percentages of NDI, also reported by Harden 
et al [placeholder ref: Harden iGBS paper 2) in this series. This study was conducted during the 
COVID pandemic. The lockdown in India caused a disruption in schooling, with pre-schoolers not yet 
enrolled, and most children not having access to any schooling. Since the exposed children were 
identified and assessed first; and the non-GBS controls recruited later, the effect of the lockdown 
may have been more pronounced in the non-GBS. Disasters including pandemics or disease 
outbreaks have been shown to cause short term and lasting effects on psychological functioning, 
behaviour and developmental trajectory of children.  
The ‘recovery continuum model’ postulates that a child’s recovery after early brain insult falls along 
a continuum that depends not just on injury related factors such as nature, severity and timing of 
insult, but also constitutional factors such as genetic make- up, gender and cognitive capacity, and 
environmental factors such as social status, access to rehabilitation and intervention. A limitation of 
this study is that due to the small sample size, confounding factors could not be studied in detail- 
this can be addressed in future studies in this population.  
Strengths of this study include using standardised multi-country approaches and NDI tools with 
trained assessors, as well as inclusion of a counterfactual with a matched non-GBS group. This study 
was based in a referral centre, and may therefore not be generalizable to other populations.  
CONCLUSION 
Children with iGBS seem at higher risk of developing motor impairments compared to a non-GBS 
group. Larger studies are needed in LMIC to estimate incidences of NDI in survivors of GBS and to 
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Figure 1: Map of the multi-country iGBS long-term follow-up studies, showing details of the India 
site. 
India was one of 5 low and middle-income countries who participated in the study. 
Figure 2: Participant flow of iGBS cases and non-iGBS children recruited  
Out of 79 iGBS survivors contacted, 35 consented for participation and completed the assessment. 
Out of 158 matched non-GBS children contacted for participation, 65 children consented and 
completed neurodevelopmental, vision and hearing assessments.  
Figure 3: Results of NDI by domain for iGBS and non- iGBS children  
Figure 3 describes impairment severity by domain in the iGBS) and non-GBS group. Unadjusted OR 
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Table 1. Demographic and health characteristics amongst survivors of invasive Group B Streptococcal 
(iGBS) in infancy and comparison cohort in India  
 iGBS cohort 
(n=35) 
Non GBS cohort 
(n=65) 
p value 
Matching criteria  
Age at assessment (months), mean (SD) 62.9 (46) 56.6 (38) 0.46 










iGBS characteristics  









GBS onset, n (%) 
Early onset (0-6 days) 







Birth history  
Birth weight, mean (SD) 2916 (510) 2944 (570) 0.81 











Birth order, n (%) 
First born 









Caregiver and household characteristics  
Highest education for main caregiver, n (%) 
Illiterate/ Primary/ Middle school  
High school/Intermediate  












Carer employment status, n (%) 
Housework  































Head of household education, n (%) 
Illiterate/ Primary/ Middle school  
High school/Intermediate  
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 iGBS cohort 
(n=35) 
Non GBS cohort 
(n=65) 
p value 


















House hold monthly income, n (%) 
Less than Rs 10000 
Rs. 10002-29972 
Rs. 29973-49961 














SES classification, n (%) 
Upper/ Upper Middle 
Lower Middle 
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Table 2: Developmental outcomes amongst survivors of GBS disease and comparison cohort 
 iGBS cohort 
(n=35) 
Non GBS cohort  
(n=65) 
p-value 
Children below 42 months n (%) 
 n= 17 n= 32  
Age at assessment (months) M (SD) 28.8 (8.3) 27.3 (8.9) 0.636 
Vision impairment  1 (6) 0 0.347 
Hearing impairment 1 (6) 0 0.378 
Bayley Scales of infant and toddler development- 3 



























Socio emotional scale Composite score 105 (27) 114 (17) 0.170 











Adaptive behaviour Composite score 82 (20) 80 (10) 0.654 
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Child Behaviour Checklist (n=45) 

































Any impairment 6 (35) 9 (28) 0.747 
Any moderate/ severe impairment 0 1 (3) 1.000 
Multi domain impairment 4 (23) 1 (3) 0.043* 
Children above 42 months n (%) 
 n= 18 n=33  
Age at assessment (months) M (SD) 95.17 (43) 84.97 (34) 0.145 
Vision impairment  1 (6) 2 (6) 0.718 
Hearing impairment 0 0  
Wechsler’s Preschool and Primary Scale of Intelligence- 4th Edition (WPPSI)/ Wechsler’s 
scale of Intelligence- 5
th
 Edition (WISC-5) 
Fluid reasoning Composite score M (SD) 100.19 (12.6) 107.9 (15.1) 0.553 
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Processing speed Composite score M (SD) 92.25 (13.1) 87.86 (14.0) 0.401 
Processing speed interpretation n (%) n=  45 
Mild impairment 
Moderate impairment 












Working memory Composite score M (SD) 100.76 (12) 107.57 (16) 0.061 
Working memory interpretation n (%) n=  47 
Mild impairment 
Moderate impairment 












Visual spatial Composite score M (SD) 95.12 (11.5) 95.20 (12.6) 0.461 
Visual spatial interpretation n (%) n=  47 
Mild impairment 
Moderate impairment 












Verbal comprehension Composite score M 
(SD) 
89.18 (10.64) 91.93 (12.31) 0.936 
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Severe impairment  
Full scale IQ Composite score M (SD) 93.78 (10.5) 99.39 (15.2) 0.069 
Full scale IQ interpretation n (%) n=  51 
Mild impairment 
Moderate impairment 













Bruininks-Oseretsky Test of Motor Proficiency (BOT 2) 
Standard scores 48.88 (10.9) 51.9 (8.6) 0.380 
Percentile rank 47.47 (30) 54.74 (25) 0.505 
Interpretation n(%) n= 48 
Mild impairment 
Moderate impairment 
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Any impairment 11 (61) 16 (48) 0.558 
Any Moderate/ Severe impairment 1 (5) 2 (6) 1.000 
Multi domain impairment 5 (27) 9 (27) 1.0 
Age groups combined n (%) 
Vision impairment  1 (5) 2 (6) 1.0 
Hearing impairment  1 (2) 0 0.372 























































Any impairment 17 (48.6) 25 (38.5) 0.397 
Moderate to severe impairment 1 (2.9) 3 (4.6) 1.000 
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